Waverly Advisors LLC purchased a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 3,184 shares of the medical research company's stock, valued at approximately $626,000.
A number of other institutional investors have also made changes to their positions in the stock. JPMorgan Chase & Co. raised its position in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock valued at $437,378,000 after acquiring an additional 583,396 shares during the period. UMB Bank n.a. increased its holdings in shares of IQVIA by 72.8% in the fourth quarter. UMB Bank n.a. now owns 401 shares of the medical research company's stock worth $79,000 after acquiring an additional 169 shares in the last quarter. Janney Montgomery Scott LLC grew its position in shares of IQVIA by 3.3% in the 4th quarter. Janney Montgomery Scott LLC now owns 36,512 shares of the medical research company's stock valued at $7,175,000 after purchasing an additional 1,172 shares during the period. Mutual Advisors LLC lifted its stake in IQVIA by 14.8% in the fourth quarter. Mutual Advisors LLC now owns 1,689 shares of the medical research company's stock valued at $334,000 after buying an additional 218 shares in the last quarter. Finally, Brighton Jones LLC boosted its stake in IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock worth $703,000 after purchasing an additional 2,537 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of equities research analysts recently issued reports on IQV shares. Mizuho dropped their target price on IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a research report on Thursday, May 15th. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Redburn Partners set a $188.00 price target on shares of IQVIA in a research note on Friday, May 23rd. Royal Bank of Canada restated an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Finally, Barclays lowered their target price on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Wednesday, May 7th. Eight investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $226.32.
Read Our Latest Stock Analysis on IQVIA
IQVIA Stock Performance
NYSE:IQV traded down $1.95 during mid-day trading on Wednesday, hitting $138.59. 1,601,507 shares of the stock were exchanged, compared to its average volume of 1,567,567. The firm's 50-day simple moving average is $153.47 and its 200 day simple moving average is $182.26. The stock has a market capitalization of $23.98 billion, a price-to-earnings ratio of 18.48, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.
IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter last year, the firm earned $2.54 earnings per share. The company's revenue was up 2.5% on a year-over-year basis. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
